ATE240738T1 - Verwendung von epithel-adhärente lactobazillen - Google Patents

Verwendung von epithel-adhärente lactobazillen

Info

Publication number
ATE240738T1
ATE240738T1 AT96908428T AT96908428T ATE240738T1 AT E240738 T1 ATE240738 T1 AT E240738T1 AT 96908428 T AT96908428 T AT 96908428T AT 96908428 T AT96908428 T AT 96908428T AT E240738 T1 ATE240738 T1 AT E240738T1
Authority
AT
Austria
Prior art keywords
pct
mannose
date sep
sec
strain
Prior art date
Application number
AT96908428T
Other languages
English (en)
Inventor
Ingegerd Adlerberth
Siv Ahrne
Bengt Jeppsson
Marie-Louise Johansson
Goeran Molin
Agnes Wold
Original Assignee
Probi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probi Ab filed Critical Probi Ab
Application granted granted Critical
Publication of ATE240738T1 publication Critical patent/ATE240738T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AT96908428T 1995-03-23 1996-03-25 Verwendung von epithel-adhärente lactobazillen ATE240738T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501056A SE9501056D0 (sv) 1995-03-23 1995-03-23 Epithelial adherent lactobacilli
PCT/SE1996/000372 WO1996029083A1 (en) 1995-03-23 1996-03-25 Epithelial adhesive lactobacilli

Publications (1)

Publication Number Publication Date
ATE240738T1 true ATE240738T1 (de) 2003-06-15

Family

ID=20397666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96908428T ATE240738T1 (de) 1995-03-23 1996-03-25 Verwendung von epithel-adhärente lactobazillen

Country Status (16)

Country Link
US (1) US6159465A (de)
EP (1) EP0817640B1 (de)
JP (1) JP4072646B2 (de)
KR (1) KR100446482B1 (de)
CN (1) CN1138551C (de)
AT (1) ATE240738T1 (de)
AU (1) AU702705B2 (de)
BR (1) BR9607538A (de)
CA (1) CA2216150C (de)
DE (1) DE69628288T2 (de)
EE (1) EE04097B1 (de)
ES (1) ES2200057T3 (de)
NO (1) NO974371L (de)
PL (1) PL184037B1 (de)
SE (1) SE9501056D0 (de)
WO (1) WO1996029083A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100376954B1 (ko) * 1995-07-31 2003-07-18 프로비 에이비 장에서집락화하는유산간균
ES2168785T5 (es) * 1997-07-05 2009-04-16 Societe Des Produits Nestle S.A. Absorcion de minerales por las celulas intestinales.
FI974643L (fi) * 1997-12-30 1999-07-01 Atria Oyj Biologinen menetelmä salmonellan eliminoimiseksi prosesseista ja rakenteista
EP1117414A1 (de) * 1998-10-01 2001-07-25 Probi Ab Reduktion von faktoren des oxidativen stresses
WO2001010448A1 (en) * 1999-08-09 2001-02-15 University Of Maryland, Baltimore Pro-gut maturation and anti-inflammatory effects of lactobacillus and lactobacillus secreted proteins, carbohydrates and lipids
WO2001030365A1 (en) * 1999-10-26 2001-05-03 Societe Des Produits Nestle S.A. Lactic acid bacteria for the treatment and/or prophylaxis of giardiasis
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
SE0004124D0 (sv) * 2000-11-10 2000-11-10 Probi Ab New use
FR2831555A1 (fr) * 2001-10-29 2003-05-02 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
FR2826020B1 (fr) * 2001-06-14 2005-02-11 Ceva Sante Animale Procede de selection de souches de bacteries lactiques a gram positif non pathogenes capables de lutter contre des infections par des bacteries pathogenes
CZ20033384A3 (cs) * 2001-06-14 2004-04-14 Ceva Sante Animale Způsob selekce kmenů nepatogenních grampozitivních mléčných bakterií
SE527555C2 (sv) * 2003-04-04 2006-04-11 Probi Ab Anti-inflammatorisk komposition innehållande tannasproducerande Lactobacillusstammar
WO2005086870A2 (en) * 2004-03-10 2005-09-22 The Board Of Trustees Of The University Of Illinois Novel lactobacillus strains and method of use
DE602005020915D1 (de) * 2004-03-23 2010-06-10 Friesland Brands Bv Mannose-spezifische adhesinen und deren vervendung
SE528382C2 (sv) * 2004-10-05 2006-10-31 Probi Ab Probiotiska lactobacillusstammar för förbättrad vaginal hälsa
JP2006180836A (ja) * 2004-12-28 2006-07-13 Marudai Food Co Ltd 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物
JP2006257077A (ja) * 2005-02-18 2006-09-28 Marudai Food Co Ltd 免疫調節剤および免疫調節食品
CN1888051B (zh) * 2005-06-28 2010-05-05 北京天佑达生物工程科技有限公司 一株植物乳杆菌及其应用
SE529199C2 (sv) * 2005-07-05 2007-05-29 Probi Ab Förstärkt absorption
CA2622951A1 (en) 2005-09-28 2007-04-05 Nordisk Rebalance A/S Treatment of ibd and ibs using both probiotic bacteria and fermented cereal as treatment effectors
AU2006325531B2 (en) 2005-12-13 2012-04-19 Exthera Medical Corporation Method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from blood
PL210465B1 (pl) 2007-06-04 2012-01-31 Inst Biotechnologii Surowic I Szczepionek Biomed Społka Akcyjna Zastosowanie kompozycji szczepów z rodzaju Lactobacillus
FR2928935B1 (fr) 2008-03-19 2011-05-20 Gervais Danone Sa Souche de lactobacillus rhamnosus.
EP2459203B1 (de) 2009-07-30 2018-10-31 DuPont Nutrition Biosciences ApS Milchsäurebakterien und bifidobakterien zur behandlung von endotoxämie
ES2861359T3 (es) 2009-12-01 2021-10-06 Exthera Medical Corp Dispositivo para eliminar citoquinas de la sangre con polisacáridos inmovilizados en superficie
AU2011209407B2 (en) 2010-01-28 2014-02-27 Ab-Biotics S.A. Probiotic composition for use in the treatment of bowel inflammation
WO2012112724A1 (en) 2011-02-15 2012-08-23 Exthera Medical, Llc Device and method for removal of blood-borne pathogens, toxins and inflammatory cytokines
BG66608B1 (bg) * 2011-05-04 2017-10-16 "Ел Би Булгарикум" ЕАД Полибактериален пробиотичен препарат
CN102618456B (zh) * 2012-02-28 2013-08-21 江南大学 一种能够缓解慢性酒精性肝损伤的鼠李糖乳杆菌及其用途
ES2647577T3 (es) 2012-06-13 2017-12-22 Exthera Medical Corporation Uso de heparina y carbohidratos para tratar el cáncer
JP2012184261A (ja) * 2012-06-21 2012-09-27 Snow Brand Milk Products Co Ltd 免疫増強剤
CN102827796B (zh) * 2012-09-03 2013-10-30 江南大学 一种具有排镉功能的植物乳杆菌及其用途
US9452205B2 (en) 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
JP6648009B2 (ja) * 2013-06-24 2020-02-14 エクステラ・メディカル・コーポレーション マンノース被覆基材を含有する血液濾過システム
AU2014346668C1 (en) 2013-11-08 2018-04-26 Exthera Medical Corporation Methods for diagnosing infectious diseases using adsorption media
DE15782250T1 (de) 2014-04-24 2017-08-10 Exthera Medical Corporation Verfahren zur Entfernung von Bakterien aus Blut unter Verwendung einer hohen Durchflussrate
CN106714669B (zh) 2014-09-22 2021-05-14 艾克塞拉医疗公司 可穿戴的血液灌流装置
RU2709464C2 (ru) 2015-09-29 2019-12-18 Кимберли-Кларк Ворлдвайд, Инк. Синергическая композиция для сохранения здорового баланса микрофлоры
EP3422943A4 (de) 2016-03-02 2019-10-16 ExThera Medical Corporation Verfahren zur behandlung von arzneimittelintoxikation
US11911551B2 (en) 2016-03-02 2024-02-27 Exthera Medical Corporation Method for treating drug intoxication
US12029748B2 (en) 2017-02-28 2024-07-09 Kimberly-Clark Worldwide, Inc. Synergistic composition for maintenance of healthy balance of microflora
WO2019103198A1 (ko) 2017-11-24 2019-05-31 주식회사 고바이오랩 락토바실러스 퍼멘텀 kbl 375 균주 및 그 용도
CN112534043B (zh) 2018-05-09 2024-04-26 Ko生物技术有限公司 副干酪乳杆菌菌株及其用途
JP7088573B2 (ja) 2018-05-23 2022-06-21 コバイオラブズ・インコーポレイテッド ラクトバチルス・ガッセリーｋｂｌ６９７株及びその使用
EP3969014A4 (de) 2019-05-16 2023-01-25 ExThera Medical Corporation Verfahren zur modulation der endothelialen glycocalyxstruktur
CN114007434A (zh) 2019-06-05 2022-02-01 森永乳业株式会社 营养组合物
CN111575223B (zh) * 2020-05-20 2022-04-15 江南大学 一种降低鼠李糖乳杆菌表面物质分泌量的方法
CN119242500A (zh) * 2024-09-30 2025-01-03 尚品健康科技(青岛)有限公司 一株母乳来源植物乳植杆菌改善过敏性疾病和调节肠道菌群的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0203586A3 (de) * 1985-05-29 1988-03-09 Pioneer Hi-Bred International Zubereitung für die Behandlung von Magen-/Darmstörungen bei Tieren
SE469875C (sv) * 1991-07-25 1997-04-14 Probi Ab Stam av tarmkoloniserande Lactobacillus samt komposition för profylax eller behandling av infektioner i magtarmkanalen
GB9124249D0 (en) * 1991-11-14 1992-01-08 Goldstein Fredric Ribbon curling and shredding device
GB2261372A (en) * 1991-11-15 1993-05-19 Gregor Reid Lactobacillus and skim milk compositions for prevention of urogenital infection

Also Published As

Publication number Publication date
CA2216150C (en) 2008-01-22
DE69628288D1 (de) 2003-06-26
CA2216150A1 (en) 1996-09-26
CN1185111A (zh) 1998-06-17
KR19980703102A (ko) 1998-10-15
ES2200057T3 (es) 2004-03-01
AU702705B2 (en) 1999-03-04
WO1996029083A1 (en) 1996-09-26
HK1017989A1 (en) 1999-12-10
CN1138551C (zh) 2004-02-18
PL322550A1 (en) 1998-02-02
US6159465A (en) 2000-12-12
DE69628288T2 (de) 2004-04-08
NO974371L (no) 1997-11-20
SE9501056D0 (sv) 1995-03-23
EE9700329A (et) 1998-06-15
BR9607538A (pt) 1998-01-06
EE04097B1 (et) 2003-08-15
NO974371D0 (no) 1997-09-22
PL184037B1 (pl) 2002-08-30
JP4072646B2 (ja) 2008-04-09
JPH11502703A (ja) 1999-03-09
EP0817640A1 (de) 1998-01-14
AU5166596A (en) 1996-10-08
EP0817640B1 (de) 2003-05-21
KR100446482B1 (ko) 2006-01-27

Similar Documents

Publication Publication Date Title
DE69628288D1 (de) Verwendung von epithel-adhärente lactobazillen
AU6040001A (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
HU9603251D0 (en) Lactobacillus strains of human origin, their compositions and uses thereof
TR200101699T2 (tr) Urogenital enfeksiyonların önlenmesi ve tedavisi için ağızdan lactobakilus uygulaması
Li et al. Association of proteases of Porphyromonas (Bacteroides) gingivalis with its adhesion to Actinomyces viscosus
Neilands et al. Parvimonas micra stimulates expression of gingipains from Porphyromonas gingivalis in multi-species communities
FR2722506B1 (fr) Composition contenant des acides nucleiques, preparation et utilisations
ATE175117T1 (de) Verwendung von lipasen zur herstellung von arzneimitteln
Sánchez et al. Identification of novel proteins secreted by Lactobacillus rhamnosus GG grown in de Mann‐Rogosa‐Sharpe broth
AU3926895A (en) Nucleic acid transfer system
GR3027620T3 (en) Treatment of mycobacterial diseases by administration of bactericidal/permeability-increasing protein products
ATE234111T1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
MY140870A (en) Nutrition supplement containing lactobacillus acidophilus, yeast and soy protein
ATE405294T1 (de) Gezielt eingesetzte agenzien zur nervenregeneration
Akesson et al. Targeting of streptococci by zoocin A
Viboud et al. Binding of enterotoxigenicEscherichia coliexpressing different colonization factors to tissue-cultured Caco-2 cells and to isolated human enterocytes
NZ336781A (en) Fibronectin binding protein compositions, antibodies thereto, and methods of use
DK0858501T3 (da) Mælkesyrebakteriepræparater samt deres anvendelse til fremstilling af kolesterolsænkende produkter
DE59611307D1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln
Titball et al. Partial purification and properties of a haemolytic activity (T-lysin) from Aeromonas salmonicida
Yamasaki et al. Surgical site infection caused by Aeromonas hydrophila presenting as necrotizing soft tissue infection after esophagectomy
Ouwehand et al. Specificity of spent culture fluids of Lactobacillus spp. to inhibit adhesion of enteropathogenic fimbriated Escherichia coli cells
PL321890A1 (en) Variants human dnase i
Hryniewicz et al. The first national external quality assessment scheme in clinical bacteriology in Poland(POLMicro I)
LeVatte Repression of the Pseudomonas aeruginosa ferripyochelin-binding protein expression by subinhibitory concentrations of antibiotics

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0817640

Country of ref document: EP